Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL299888 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL299887 | 1.00 | CA2 (0.46) | CA2SLC34A1FDPSBLMKDM4E | |
| Phosphoric Acid SCHEMBL8740564 | 1.00 | CA2 (0.46) | CA2SLC34A1FDPSBLMKDM4E | |
| Phosphoric Acid SCHEMBL11326850 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL28966239 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL28689894 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL28150339 | 0.94 | CA2 (0.42) | CA2SLC34A1FDPSBLMKDM4E | |
| Phosphoric Acid SCHEMBL28206436 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL28150340 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL181164 | 0.88 | CA2 (0.46) | CA2SLC34A1FDPSBLMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999098-B2 | Triphosphate oligonucleotide modification reagents and uses thereof | SOLULINK BIOSCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20070179288-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2007-08-02 | — | — | US | disclosed |
| US-7173125-B2 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2007-02-06 | — | — | US | disclosed |
| US-20040214199-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2004-10-28 | — | — | US | disclosed |
| US-6686461-B1 | HYDRAZINO, OXYAMINO AND CARBONYL-BASED MONOMERS AND METHODS FOR LABELLING OF OLIGONUCLEOTIDES WITHOUT THE NEED FOR POST-SYNTHETIC MODIFICATION | SOLULINK BIOSCIENCE, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1305327-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | Schwartz, David A. (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010432-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214199-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | RNGTT, DUT, NUDT1 | CA2 2935/4885SLC34A1 1108/4885FDPS 1899/4885 |
| US-20070179288-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | RNGTT, DUT, NUDT1 | CA2 3021/4885SLC34A1 1118/4885FDPS 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.